NCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
Clinical Trials
25 trialsNCT07469046 2026-03-13
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Not yet recruiting
NCT06483906 2026-03-03
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05906914 2026-02-04
CHA
First Affiliated Hospital of Zhejiang University
Phase 2 Completed
NCT07163910 2025-11-18
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Zhongda Hospital
Phase 2 Recruiting
NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT07159906 2025-09-08
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
First Affiliated Hospital of Zhejiang University
Phase 1/2 Not yet recruiting
NCT06855810 2025-08-26
CCCG-TALL-2025
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3 Recruiting
NCT06742463 2024-12-19
VHAG in Treating R/R T-ALL/LBL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT06221683 2024-08-22
GMCAII
Children's Hospital of Soochow University
Phase 2 Recruiting
NCT05805098 2023-04-07
VHA
The First Affiliated Hospital of Soochow University
Phase 2/3 Recruiting
NCT04248595 2022-09-08
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Zhongda Hospital
Phase 2 Unknown
NCT05457361 2022-07-14
VAH Versus VA for Salvage Therapy of R/R-AML
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT04722952 2021-12-03
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT02159872 2021-06-09
Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03135054 2020-12-10
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Unknown
NCT03170895 2020-03-30
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
The University of Hong Kong
Phase 2 Completed
NCT01873495 2019-09-24
Omacetaxine for Consolidation and Maintenance
Emory University
Phase 2 Terminated
NCT04083911 2019-09-10
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT01272245 2018-05-30
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02141477 2018-02-13
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00004933 2016-07-04
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT02029417 2016-05-09
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00003239 2012-07-30
Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed